Market Report, "Global Lung Cancer Therapeutics Market 2015-2019", published

From: Fast Market Research, Inc.
Published: Mon Dec 22 2014

Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Non-small cell lung cancer is the commonest type of lung cancer and forms almost 85-90 percent of the total cases diagnosed. It grows and spreads slowly. Smoking is considered as a major cause of lung cancer, though lung cancer also occurs in non-smokers. Non-small cell lung cancer is of three types: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Small cell lung cancers form roughly 10-15 percent of all the diagnosed cases of lung cancer. There are two types of small cell lung cancer: small cell carcinoma and combined small cell carcinoma. It can be classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer cannot be cured using current therapies available in the market. Some of the common symptoms associated with lung cancer are chest pain, persistent cough, blood in sputum, fatigue, loss of appetite, weight loss, shortness of breath, and wheezing. Both small cell lung cancer and non-small cell lung cancer are recurrent in nature, which are difficult to cure.

Full Report Details at

TechNavio's analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 3.83 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Lung Cancer Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of non-small cell lung cancer and small cell lung cancer.

The Global Lung Cancer Therapeutics market is segmented based on the type of molecule used for the treatment of lung cancer, which include:

* Biologics
* Small molecules

In addition, the market is also segmented based on the route of administration followed for the treatment of lung cancer, which include:

* Oral
* Parenteral

TechNavio's report, Global Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

* Americas

Key Vendors

* AstraZeneca
* Celgene
* Eli Lilly
* F. Hoffmann-La Roche
* Pfizer

Other Prominent Vendors

* Abbvie
* Aetna
* Agennix
* Amgen
* Boehringer Ingelheim
* Celldex
* Eisai
* GlaxoSmithKline

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014
- Non-Small Cell Lung Cancer - Pipeline Review, H1 2014
- Small-Cell Lung Cancer - Pipeline Review, H2 2014
- Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market
- NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »